Roivant Sciences (ROIV) PT Lowered to $13 at Truist Securities on ARU-1801 Discontinuation, Buy Reiterated Jun 28, 2022 04:41PM
ONO Collaboration Extension "Signifying Forward Progress" - Mizuho Securities Reiterates Buy Rating on Fate Therapeutics (FATE) Jun 28, 2022 08:18AM
H.C. Wainwright Reiterates Buy Rating, $15 Price Target on Biophytis SA (BPTS) Jun 28, 2022 06:08AM
ESSA Pharma (EPIX) PT Raised to $23 at Oppenheimer, Sees "Much Larger Market Opportunity" for 7386 + enzalutamide Jun 28, 2022 06:07AM
Arcutis (AQRT) Has Significantly More Upside, roflumilast is Key Driver - Mizuho Securities Bullish on Stock Jun 28, 2022 06:05AM
View Older Stories

Jun 28, 2022 05:54AM Expect Spero Therapeutics (SPRO) to Seek Partnership for tebipenem - Cowen Reiterates Market Perform on Stock
Jun 27, 2022 09:17AM Etsy (ETSY) Downgraded at Needham & Company on Macro Outlook
Jun 27, 2022 06:14AM Oppenheimer Reiterates Perform Rating, $94 Price Target on BioMarin Pharmaceutical (BMRN) on Positive CHMP Opinion for Roctavian
Jun 24, 2022 10:59AM "See Interesting Upside Potential for REGN" - BMO Capital Reiterates Regeneron (REGN) at Outperform on NTLA Data
Jun 24, 2022 09:14AM Altria (MO) Upgraded at Morgan Stanley on Price Dip, PT Lowered Following JUUL Ban
Jun 24, 2022 07:50AM Stifel Reiterates Buy Rating on BioMarin Pharmaceutical (BMRN) Following Positive CHMP Recommendation for valrox
Jun 24, 2022 07:28AM Tesla's (TSLA) PT Cut at Credit Suisse on Short-Term Issues, but 'Long-Term Bull Thesis Intact'
Jun 24, 2022 06:21AM Sarepta's (SRPT) SRP-5051 Clinical Hold Likely Resolved in Near-Term - Mizuho Securities Reiterates Buy Rating and $160 PT
Jun 24, 2022 06:13AM William Blair Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
Jun 24, 2022 06:09AM Sarepta's (SRPT) Clinical Hold Should not Affect Timeline for Development and Approval - Needham & Company Reiterates Buy Rating, $150 PT
Jun 24, 2022 06:06AM Sarepta (SRPT) Has 10% Pull Back Risk on SRP-5051 Hold - Raymond James Reiterates Stock at Market Perform
Jun 23, 2022 11:26AM Netflix (NFLX): Recession May Lead to Incremental Churn, BofA Securities Slashes PT
Jun 23, 2022 08:56AM Apple (AAPL) 'Not Inexpensive', Bernstein Says
Jun 23, 2022 06:42AM Needham & Company Reiterates Buy Rating, $48 Price Target on Xenon Pharmaceuticals (XENE) on New XEN1101 Data
Jun 23, 2022 06:36AM KOL Sees 70% of Phase 3 APOLLO-B - Needham & Company Bullish on Alnylam (ALNY) Ahead of patisiran Readout
Jun 23, 2022 06:06AM Xenon's (XENE) XEN1101 Has Best in Class Potential, Company is Trading at Attractive Value - William Blair Bullish on Stock
Jun 22, 2022 05:44PM Greater Competition Does Not Impact Investment Thesis - Cantor Fitzgerald Reiterates Amarin Corporation (AMRN)at Overweight
Jun 22, 2022 11:51AM 22nd Century (XXII) Soars on Biden Admin Decision, Here's All You Need to Know
Jun 22, 2022 08:29AM 22nd Century (XXII) "Has the Technology to Solve Industry's Problem" - Dawson James Bullish on XXII
Jun 22, 2022 08:21AM Precision's (DTIL) Novartis Deal 'Adds Validation' While Financing Could Improve Sentiment, Analyst Says
Jun 22, 2022 08:20AM Athira Pharma (ATHA) Reiterated at Buy by Stifel Despite Price Plunge, Cites $7 Cash per Share and Awaits Further Updates
Jun 22, 2022 07:30AM "We're Positive Into Ph3 Ensifentrine Data In August" - Truist Securities Bullish on Verona Pharma (VRNA) Ahead of Key Readout
Jun 22, 2022 06:40AM Oppenheimer Reiterates Outperform Rating, $5 Price Target on Acasti Pharma (ACST)
Jun 22, 2022 06:13AM Stifel Reiterates Buy Rating on Precision BioSciences (DTIL) Over Equity Raise; Novartis Deal Could Net "Up to $1.4B"
Jun 22, 2022 06:10AM CRISPR Therapeutics (CRSP) PT Lowered to $55 at Stifel on Lower CAR-T Estimates
Jun 22, 2022 06:08AM H.C. Wainwright Reiterates Buy Rating, $20 on Paratek Pharmaceuticals (PRTK) on NUZYRA's Fast-Track Designation
Jun 22, 2022 06:05AM Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
Jun 21, 2022 09:50AM Valneva (VALN) Announces 8.1% Stake Taken by Pfizer (PFE), Shares Soar
Jun 21, 2022 08:42AM Acadia (ACAD) Shares Plunge on Negative NUPLAZID AdCom Vote, Prompting JP Morgan Downgrade
Jun 15, 2022 09:43AM "Confused By Stock Reaction, Do Not View Documents as Supportive" - Stifel Weighs in Acadia Pharma (ACAD) Stock Soars
Jun 13, 2022 09:28AM Bluebird (BLUE) Surges on Positive FDA ADCom, Analyst Says beti-cel Could Change the Treatment Paradigm
Jun 9, 2022 05:21AM Oppenheimer Reiterates Outperform Rating on Veru (VERU) Ahead of sabizabulin EMA Decision
Jun 8, 2022 05:43PM "Encourage Investors to Acquire Shares" - Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) with $21 Price Target
Jun 8, 2022 05:13PM Ionis' (IONS) "Data for Eplontersen are Highly Likely to be Positive on Efficacy" - Stifel Reiterates Hold Ahead of Phase 3 Readout with $33 Price Target
Jun 8, 2022 04:41PM BioReference "Collaboration Further Validates OVA1Plus Offering" - Cantor Fitzgerald Bullish on Aspira Women’s Health (AWH) with Overweight Rating and $6 Price Target
Jun 8, 2022 04:39PM "Updated PBCAR0191 Efficacy Looks Compelling" - Stifel Reiterates Buy Rating on Precision BioSciences (DTIL) with $16 Price Target
Jun 8, 2022 07:50AM Stifel Reiterates Hold Rating on Cardiovascular Systems (CSII) Following COO Departure
Jun 8, 2022 06:17AM "There is Upside to Market Potential and Our Outlook" of SY-1425 - Brookline Capital Markets Bullish on Syros Pharmaceuticals (SYRS) with Buy Rating and $19 Price Target
Jun 8, 2022 06:15AM "Maintain Cautious Optimism" on CUE-101 - Oppenheimer Reiterates Outperform Rating on Cue Biopharma (CUE) with $26 Price Target
Jun 8, 2022 06:13AM Cowen Reiterates Outperform Rating on Twist Bioscience (TWST)
Jun 8, 2022 06:10AM Cowen Reiterates Outperform Rating on Mirati Therapeutics (MRTX)
Jun 8, 2022 06:08AM "PH94B Has Potential to Open Several New Markets" - William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)
Jun 8, 2022 05:56AM Maintain "Confidence Bylvay Could Become the Best-in-Class Agent" - William Blair Reiterates Outperform Rating on Albireo Pharma (ALBO)
Jun 8, 2022 05:54AM "Look to Take Advantage of the Recent Weakness" - Oppenheimer Bullish on PDS Biotechnology Corp (PDSB) In Face of Selloff
Jun 7, 2022 05:05PM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $32 at Stifel on "Bear Biotech Market", "Remain Believers in Acute HAE Opportunity, KVD824 Looking Most Underappreciated"
Jun 7, 2022 01:13PM ANX005 Results "Suggest a Potential Path Forward" - Needham & Company Reiterates Buy Rating, $24 Price Target on Annexon Biosciences (ANNX)
Jun 7, 2022 10:49AM Oppenheimer Reiterates Outperform Rating, $13 Price Target on Seres Therapeutics (MCRB)
Jun 7, 2022 05:45AM "Remain Encouraged by VBI-1901's Performance" - Oppenheimer Reiterates VBI Vaccines (VBIV) at Outperform with $8 Price Target
Jun 7, 2022 05:36AM Cantor Fitzgerald Reiterates Overweight Rating, $335 Price Target on Eli Lilly (LLY)
Jun 7, 2022 05:33AM BMO Capital Reiterates Mirati Therapeutics (MRTX) at Outperform on Latest Adagrasib Data, but "Need to See Additional Data from Amgen" to Understand Market Potential
View Older Stories